Glioblastomas rank among the most lethal of human cancers, with current therapies offering only palliation 1 . Glioblastomas display striking intertumoral heterogeneity in transcriptional programs and genetic lesions 2,3 , but glioblastomas also phenocopy aberrant organ systems, with intratumoral heterogeneity within the neoplastic compartment derived from genetic and epigenetic forces, leading to cellular hierarchies with self-renewing BTICs at the apex 4-6 . Normal neural progenitor cells (NPCs) are functionally defined by self-renewal and differentiation into relevant lineages 7 . BTICs share these features but are distinguished by their frequency, proliferation, aberrant expression of differentiation markers, chromosomal abnormalities and tumor formation. While the nature of BTICs remain controversial because of unresolved issues over cell of origin and purification, they have generated substantial interest because of their resistance to conventional therapies, evasion of antitumor immune responses, promotion of tumor angiogenesis and invasion into normal tissues [8] [9] [10] [11] [12] .
a r t I C l e S Glioblastomas rank among the most lethal of human cancers, with current therapies offering only palliation 1 . Glioblastomas display striking intertumoral heterogeneity in transcriptional programs and genetic lesions 2, 3 , but glioblastomas also phenocopy aberrant organ systems, with intratumoral heterogeneity within the neoplastic compartment derived from genetic and epigenetic forces, leading to cellular hierarchies with self-renewing BTICs at the apex [4] [5] [6] . Normal neural progenitor cells (NPCs) are functionally defined by self-renewal and differentiation into relevant lineages 7 . BTICs share these features but are distinguished by their frequency, proliferation, aberrant expression of differentiation markers, chromosomal abnormalities and tumor formation. While the nature of BTICs remain controversial because of unresolved issues over cell of origin and purification, they have generated substantial interest because of their resistance to conventional therapies, evasion of antitumor immune responses, promotion of tumor angiogenesis and invasion into normal tissues [8] [9] [10] [11] [12] .
Evolving models of cancer hallmarks have integrated metabolism as an essential feature of cellular transformation 13 . Metabolic changes are not simply a result of oncogenesis, as mutations in key enzymes are primary tumor-initiating lesions 13 . Isocitrate dehydrogenase 1 (IDH1) is mutated in most low-grade gliomas and secondary glioblastomas, leading to formation of an oncometabolite causing cellular dedifferentiation 14, 15 . However, most glioblastomas express wild type IDH1, suggesting potential alternative regulation of metabolism 14 . Like most cancers, glioblastomas display derangement of metabolism to promote a shift toward glycolysis, known as the Warburg effect 16 . While all tumor cells display dysregulation of metabolic pathways, the differential growth patterns of BTICs suggest that these tumor subpopulations have metabolic features that distinguish them from the tumor bulk [17] [18] [19] [20] . Recent studies suggest that the molecular machinery of nutrient sensation instructs the behavior of stem cells, particularly embryonic and hematopoietic stem cells 21 . As mitochondria represent the central metabolic organelle, mitochondria offer a potential link between cellular metabolism and differentiation state.
Mitochondria are highly dynamic organelles that synergize with the central cellular state 22 . To meet specific cellular demands of different cell types over time, cellular biogenesis is mediated through dynamic mitochondrial fusion and fission. Mitochondrial dynamics are tightly coordinated in association with the cell cycle and state, with complex structural and functional interactions leading to fusion and fission of mitochondria to alter the balance of oxidative phosphorylation, eliminate damaged mitochondrial components (for example, mitochondrial DNA) and regulate reactive oxygen species 22 . Embryonic stem cell maintenance and lineage commitment is regulated by mitochondrial dynamics [23] [24] [25] . Mitochondrial fission removes damaged mitochondrial components through mitophagy, but excessive fission may contribute to Parkinson's and Huntington's diseases 22 . Cancers, including glioblastomas, have increased rates of mitochondrial fission [26] [27] [28] [29] [30] [31] [32] . Thus, mitochondrial fission may be related to stem cell biology, beneficial for cancer and destructive in a r t I C l e S normal brain. Mitochondrial dynamic fusion and fission mediators have been closely linked to cell fate determination and development 33 . Acquired alterations in these mitochondrial regulators occur in neurodegenerative diseases, vascular disorders and cancer. Inhibitors of mitochondrial fission, such as mitochondrial division inhibitor-1 (Mdivi-1), may ameliorate neurodegenerative diseases and reduce the cardiotoxicity of chemotherapy 34, 35 .
Here we interrogated the role of mitochondrial form and functional control in the cellular hierarchy of the most common primary intrinsic brain tumor, glioblastoma, using validated and well characterized models reflecting the tumor hierarchy 8, 9, 19, 36, 37 . As metabolic control offers a potential node upon which diverse extrinsic and intrinsic cellular signaling pathways converge, these studies may inform the development of anticancer therapies.
RESULTS

BTICs display fragmented mitochondrial morphology
To investigate mitochondrial control in BTICs, we isolated functionally validated matched BTIC and non-BTIC tumor cell populations from patient-derived xenografts. Tumorsphere culture is often used to enrich for BTICs, but this methodology prevents the prospective comparison of BTICs and non-BTIC tumor cells needed for these studies. Using cell surface markers immediately upon tumor collection prevents the loss of information as cell surface markers mediate interactions with the tumor microenvironment. Glioblastomas display substantial intertumoral heterogeneity, so it is not surprising that enrichment markers for BTICs are not universally informative. CD133 (PROMININ1) is the most widely used BTIC marker but is also controversial because of its technical challenges and variable expression patterns. However, we and others have repeatedly demonstrated in our models that CD133 used immediately on patient tumor specimens or xenografts is informative of functional BTICs as measured by stem cell marker expression and in vitro and in vivo limiting dilution, including the models included in this study 4, 8, 9, 19, 36, 37 .
Therefore, our claim of BTIC identity is based on functional criteria, not markers. As culture and xenograft conditions can induce drift, we used both xenografts and cultures at early passage (<5 passages). For maintenance, BTICs and non-BTIC tumor cells were cultured separately in optimal media, but for every experiment, all cells were cultured under identical conditions and media. The cellular hierarchy was revalidated functionally (data not shown).
Using this selection system, we compared the mitochondrial morphology of BTICs with non-BTIC tumor cells using a mitochondrial marker (translocase of outer mitochondrial membranes 20 kDa, TOM20) and three-dimensional Imaris image reconstruction of images obtained from confocal microscopy (Bitplane, South Winsor, CT). Mitochondria in BTICs were more fragmented and less tubular than in matched non-BTIC tumor cells (Fig. 1a,b) . In line with these observations, electron microscopic examination confirmed shorter, rounded mitochondria in BTICs as compared with elongated, tubular structures in non-BTIC tumor cells (Fig. 1c,d ). Taken together, these findings suggest that mitochondrial fragmentation may be a distinctive feature of BTICs. npg a r t I C l e S mitochondrial fission, while MFN1 (mitofusin 1) and MFN2 are required for outer membrane fusion, and OPA1 (optic atrophy 1) is required for inner membrane fusion 22 .
DRP1 phosphorylation controls BTIC mitochondrial morphology
On the basis of differences in mitochondrial length, we interrogated the expression levels of these proteins. We detected no consistent differences in whole cell protein levels of central mediators between matched BTICs and non-BTIC tumor cells isolated from short-term patient-derived xenografts ( Supplementary Fig. 1 ), suggesting possible regulation at the post-translational level. Phosphorylation of DRP1 on Ser616 enhances DRP1 activity, whereas phosphorylation of DRP1 on Ser637 represses function 38, 39 . We quantified levels of phosphorylated DRP1 at Ser616 and Ser637 in matched cultures of BTICs and non-BTIC tumor cells from short-term xenografts by immunoblot (Fig. 2a ). In every model tested, BTICs displayed strikingly elevated activating DRP1 phosphorylation (Ser616) and downregulated inhibitory DRP1 phosphorylation (Ser637) levels compared to matched non-BTIC tumor cells. To address the possible concern regarding CD133 as a marker, we used an alternative marker, stage-specific embryonic antigen 1 (SSEA1, or CD15), which has been suggested as marker of BTICs 40 . In confirmation of our results with CD133, SSEA1-positive cells displayed an identical pattern of activated DRP1 relative to non-BTIC tumor cells (Fig. 2b) . For yet another confirmation of specific activation of DRP1 in BTICs independent of the CD133 marker, we demonstrated coexpression of DRP1 phosphorylated on Ser616 and the BTIC markers SOX2 and OLIG2 by immunofluorescence staining of human primary glioblastoma tissue sections (Fig. 2c) . To further rule out an effect of culture conditions underlying these observations, we also confirmed the results using BTICs and non-BTIC tumor cells directly isolated from primary glioblastoma clinical specimens without culture (Fig. 2d) . To determine the relationship between cellular differentiation and DRP1 regulation, we induced differentiation in BTICs and found a marked switch in DRP1 phosphorylation from the activating modification (Ser616) to the inhibitory one (Ser637) (Fig. 2e) , indicating that dynamic regulation of DRP1 by phosphorylation is important for BTIC selfrenewal and differentiation. Collectively, these findings support the idea that DRP1 is hyperactivated in BTICs.
To determine whether DRP1 phosphorylation is critical for the mitochondrial morphological change between BTICs and non-BTIC tumor cells, we constructed a gain-of-function DRP1 containing both S616E (to mimic activating phosphorylation) and S637A (to block inhibitory phosphorylation) mutations. Overexpression of DRP1 S616E,S637A in non-BTIC tumor cells potently induced remodeling of mitochondria (Fig. 3a-c) . Mitochondria in non-BTIC tumor cells transduced by lentivirus expressing mutated DRP1 S616E,S637A became more fragmented and less elongated than cells that expressed npg a r t I C l e S a control vector ( Fig. 3a-c) . Furthermore, forced expression of DRP1 S616E,S637A induced expression of some, but not all, selected core stem cell regulators ( Fig. 3d ) and repression of differentiation markers ( Fig. 3e ) as compared to vector control. Expression of DRP1 S616E,S637A was not sufficient to induce tumorsphere formation (a surrogate marker of self-renewal) or in vivo tumor formation (data not shown), suggesting that DRP1 activity alone is not sufficient to fully reprogram non-BTIC tumor cells into BTICs. Together, these results demonstrate that hyperactivated DRP1 is essential for mitochondrial fission in the tumor hierarchy.
DRP1 targeting decreases BTIC tumorigenicity
As induced differentiation of BTICs ablates the preferential hyperactivation of DRP1, suggesting a potential function for DRP1 in BTIC biology, we interrogated the requirement for DRP1 function in BTIC maintenance. We developed two independent, non-overlapping small hairpin RNA lentiviral constructs to knock down DRP1 (designated hereafter shDrp1#1 and shDrp1#2) and compared them to a control shRNA sequence that does not target mammalian mRNA, which serves to rule out off target effects (non-targeting control, NT shRNA). DRP1 shRNAs significantly reduced DRP1 protein expression on immunoblot (Fig. 4a) .
We then examined the phenotypic consequences of shRNA-mediated reduction of DRP1 expression. Silencing DRP1 significantly decreased the growth of two BTIC models ( Fig. 4a) , whereas there was no effect on non-BTIC tumor cells or human NPCs (Supplementary Fig. 2 ), further supporting the preferential requirement for DRP1 in BTICs. To determine whether targeting DRP1 also influences tumorsphere formation, we performed an in vitro limiting dilution assay in BTICs expressing non-targeting control shRNA or DRP1-directed shRNAs. Targeting DRP1 resulted in a more than tenfold decrease in the frequency of tumorsphere formation and fourfold or greater decrease in the tumorsphere 
3565 Non-BTICs (Fig. 4b,c) . BTIC assessment requires in vivo tumor growth, so we evaluated the potential antitumor effects of DRP1-directed interventions in vivo. BTICs transduced with either of two non-overlapping DRP1-targeting shRNAs or control NT shRNA were transplanted into the brains of immunocompromised mice. Animals bearing BTICs expressing shDrp1 displayed significantly reduced tumor formation and increased tumor latency and survival relative to those bearing BTICs expressing NT shRNA (Fig. 4d,e) . Together, our data demonstrate that DRP1 is required to maintain the tumorigenic potential of BTICs and that attenuation of DRP1 expression results in a loss of BTIC phenotypes, including proliferation, self-renewal and tumor formation.
Pharmacologic blockade of DRP1 inhibits BTIC growth
Mdivi-1, a selective, cell-permeable small molecule inhibitor of the DRP1 GTPase activity, has emerged as a promising proof-of-concept therapeutic agent for stroke, myocardial infarction and neurodegenerative diseases 22, 34, 35 . Mdivi-1 has activity against established cancer cell lines in vitro [27] [28] [29] [30] [31] , suggesting that inhibition of mitochondrial fission may be effective against tumor cells. In accord with the results of DRP1 knockdown experiments, blocking DRP1 activity with Mdivi-1 significantly decreased the growth of BTICs (Fig. 5a) . Furthermore, Mdivi-1 treatment dramatically induced apoptosis measured by both Annexin V staining and PARP cleavage in BTICs but not non-BTIC tumor cells or NPCs (Fig. 5b,c and data not shown) . We validated the effects of Mdivi-1 treatment on mitochondrial morphology both in vitro (Supplementary Fig. 3a ) and in vivo (Supplementary Fig. 3b) .
Next, we sought to evaluate the potential antitumor effects of Mdivi-1 in vivo. We orthotopically implanted BTICs into the brains of immunocompromised mice. Three days after implantation, mice were treated for 5 d by tail vein injection with Mdivi-1 or vehicle control (DMSO). Mdivi-1 treatment increased tumor latency and survival, with no evidence of toxicity ( Fig. 5d and data not shown) . Taken together, our findings support the efficacy of Mdivi-1 against BTICs growth and tumor formation, offering a new model for targeting stem-like brain tumor cells.
DRP1 inhibition induces AMPK activation in BTICs
On the basis of the function of DRP1 in controlling mitochondrial fission, we investigated BTIC metabolism in the context of disrupting DRP1 expression using a cell mitochondrial stress test kit (Seahorse Bioscience) that uses pharmacologic inhibitors and activators of mitochondrial function to measure mitochondrial respiration and proton excretion in real time. Initial basal respiration is disrupted by oligomycin treatment to determine ATP production (and proton leak), followed by trifluorocarbonylcyanide phenylhydrazone (FCCP) to stimulate maximal respiration, followed by antimycin A and rotenone to inhibit all mitochondrial respiration. FCCP stimulates mitochondrial respiration by uncoupling ATP synthesis from electron transport, while oligomycin and antimycin A inhibit respiration by inhibiting ATP synthase and oxidation of ubiquinol in the electron transport chain, respectively. DRP1 depletion dramatically decreased BTIC oxygen consumption rate, leading to mitochondrial dysfunction (Supplementary Fig. 4a) .
AMP-activated protein kinase (AMPK) is a central cellular sensor of energy stress, suggesting a potentially critical function in determining the survival of cells under metabolic stress. Using a pharmacologic npg a r t I C l e S activator of AMPK, we found that AMPK activation decreased BTIC growth and induced caspase activation ( Supplementary Fig. 4b,c) , a result concordant with studies in glioma cell lines 41 , phenocopying DRP1 targeting. We therefore interrogated a potential link to AMPK activation under DRP1 inhibition in BTICs. DRP1 inhibition by either shRNA knockdown (Fig. 6a) or treatment with Mdivi-1 (Fig. 6b) led to upregulation of AMPK activation, measured by increased phosphorylation of AMPKα. To determine whether AMPK regulation may serve as a critical downstream mediator of DRP1, we interrogated the potential for rescuing the phenotype caused by DRP1 targeting. While knocking down AMPKα by itself had minimal effect on BTIC growth or tumorsphere formation, targeting AMPKα expression in the context of DRP1 inhibition rescued both the BTIC growth defect (Fig. 6c) and the compromised tumorsphere formation capacity (Fig. 6d) , which strongly supports AMPKα as a critical downstream mediator of BTIC response following DRP1 inhibition. Collectively, our results suggest that DRP1 serves as a critical node in the response of BTICs to metabolic stress through AMPK regulation.
CDK5 activates DRP1 in BTICs
To determine the molecular mechanism activating DRP1 in BTICs, we investigated potential kinases regulating the phosphorylation status of DRP1. Cyclin-dependent kinase 1 (CDK1) has been reported to phosphorylate DRP1 on Ser616 (ref. 33 ). CDK family kinasesespecially CDK1, CDK2 and CDK5-often share substrates. To determine whether the CDKs regulate BTIC DRP1 Ser616 phosphorylation, we treated BTICs with roscovitine, a pan-CDK1/2/5 inhibitor, and found that DRP1 Ser616 phosphorylation was significantly reduced (Fig. 7a) , with associated loss of fragmented mitochondrial morphology (Supplementary Fig. 5 ). In contrast, treatment with BMS-265246, a CDK inhibitor more specific for CDK1/2, did not alter DRP1 Ser616 phosphorylation (Fig. 7b) or mitochondrial morphology ( Supplementary Fig. 5 ), indicating that CDK5 may be the dominant regulating kinase responsible for DRP1 Ser616 phosphorylation in BTICs. We screened the expression of the CDKs in matched BTICs and non-BTIC tumor cells and found that both CDK1 and CDK5 were preferentially expressed by BTICs in three different tumors (Fig. 7c) .
To determine whether CDK5 can directly phosphorylate DRP1, we performed an in vitro kinase assay with CDK5, its regulatory partner cyclin-dependent kinase 5, regulatory subunit 1 (p25, CDK5R1) and glutathione S-transferase (GST)-tagged DRP1 (wild type or S616A mutant) and found that CDK5 directly phosphorylated DRP1 on the Ser616 site (Fig. 7d) . RNA interference against CDK5, but not CDK1, resulted in specific diminished DRP1 Ser616 phosphorylation (Fig. 7e) . We next interrogated the functional importance of CDK5 in the regulation of mitochondrial morphology using the mitochondria marker npg a r t I C l e S TOM20. Targeting CDK5 expression by shRNA in two BTIC models resulted in less fragmentation of mitochondria (Fig. 7f) and inhibition of proliferation and tumorsphere formation ( Supplementary  Fig. 6 ). While a contribution from CDK1 cannot be completely ruled out, these results strongly suggest that CDK5, which is expressed in postmitotic neurons and is critical in brain development and neurodegenerative diseases, may be an upstream driver of mitochondrial fission and metabolic control in BTICs through direct activation of DRP1 (Supplementary Fig. 6c ).
CAMK2 inhibits DRP1 in non-BTIC tumor cells
To determine the inhibitory regulation of DRP1 in non-BTIC tumor cells, we screened potential upstream regulators of the inhibitory phosphorylation event (phospho-DRP1 Ser637 ) in non-BTIC tumor cells. Calcium/calmodulin-dependent protein kinase type 1 (CAMK1) has been previously reported to phosphorylate DRP1 Ser637 (ref. 42 ), so we targeted global CAMK function by a pan-CAMK pharmacologic inhibitor, KN93. We found downregulation of DRP1 Ser637 phosphorylation in non-BTICs upon KN93 treatment (Supplementary Fig. 7a ), but phospho-DRP1 Ser637 phosphorylation was also compromised by treatment with a CAMK2-specific inhibitor, autocamptide-2-related inhibitor peptide (AIP) (Supplementary Fig. 7b ). These results are consistent with the observation that expression of CAMK2 is higher in non-BTIC tumor cells, while CAMK1 does not display preferential expression between BTICs and non-BTIC tumor cells (Supplementary Fig. 7c ).
We next interrogated the functional importance of CAMK2 in the regulation of mitochondrial morphology. AIP treatment, inhibiting CAMK2, in non-BTIC tumor cells induced a shift toward fragmented mitochondria (Supplementary Fig. 7d) , supporting CAMK2 as a selective antagonist of DRP1 function in non-BTIC tumor cells (Supplementary Fig. 7e) . Collectively, we propose that CDK5 activates DRP1 through phosphorylating the Ser616 site in BTICs while CAMK2 inhibits DRP1 activity through phosphorylation of Ser637 in non-BTIC tumor cells, creating a competitive yoked control of metabolism in the tumor hierarchy.
Mitochondrial morphological control informs prognosis
Our findings support a model in which DRP1-mediated mitochondrial fission distinguishes BTICs. To determine the clinical relevance of these findings, we performed a combination of tissue analysis and in silico studies. DRP1 can be regulated at both the expression and activity levels, so we performed immunohistochemistry of DRP1 using a new tissue microarray with normal brain and glioblastoma tissues. Total DRP1 levels were similar in normal and neoplastic brain tissues, but activating phosphorylation of DRP1 (DRP1 Ser616 ) was selectively increased in glioblastomas (Fig. 8a) . The clinical significance of these findings was supported by a strong inverse correlation between phosphorylation of DRP1 on Ser616 and poor survival of patients with glioblastoma (Fig. 8b) .
We then examined the downstream (AMPK) and upstream (CDK5 and CAMK2) regulatory nodes of DRP1 for clinical significance. Because we found that these regulators were all controlled at the expression level in BTICs, we interrogated available in silico glioblastoma databases. Using the large National Cancer Institute Repository for Molecular Brain Neoplasia Data (REMBRANDT) glioma data set, we found that upregulation of PRKAA2 (AMPKα2) mRNA twofold or greater in all glioma samples (mixed grade) correlated with a significant increase in patient survival (Fig. 8c) . CDK5 and CAMK2 regulate DRP1 in opposite ways, with high levels of CDK5 expected to associate with higher DRP1 activity and CAMK2 with lower DRP1 activity. The REMBRANDT database confirmed that higher CDK5 expression correlated with shorter patient survival (Fig. 8d) while higher CAMK2A and CAMK2G expression was associated with longer patient survival (Fig. 8e,f) . Of note, mRNA gene expression signatures of putative BTIC markers (SOX2, OLIG2, POU5F1 and SALL2) did not npg a r t I C l e S predict patient survival independent of tumor grade (data not shown). Likewise, each of our targets was associated with tumor grade and so lacked prognostic prediction independent of tumor grade (data not shown). A combined signature of PRKAA2 low CDK5 high CAMK2A low CAMK2G low demonstrated strong dichotomization of mixed-grade glioma patient survival (Supplementary Fig. 8 ). These data support clinical importance of the CDK5/CAMK2-DRP1-AMPK signaling axis in glioma.
DISCUSSION
Glioblastomas rank among the most lethal of cancers, with decades of research adding only a few months to the median survival of patients afflicted with these cancers 1 . The explanation for the failure of current therapy to extend patient survival has many causes, but one contributing force may be the presence of complex intratumoral heterogeneity derived from heterogeneous expression of oncogenic drivers as well as cellular hierarchies that phenocopy the normal brain hierarchy, albeit with aberrant control: that is, BTICs. Targeting BTICs has proven daunting because of the resistance of these cells to pathways that have served as the basis for most cancer treatments 8, 43 , leading to new discovery models informed by stem cell biology. The development of anti-BTIC therapies has been largely informed by targeting core stem cell pathways described in development or tissue homeostasis. These approaches have yielded significant promise, but it is possible that targeting aberrant molecular control of BTICs distinct from that of normal neural stem cells may offer even greater benefit in treating brain cancer patients. Normal neural stem cells are tightly regulated because they have the ability to undergo sustained proliferation. In response, neural stem cells reside in specific niches from which their derive maintenance cues but are also constrained in proliferation, and they undergo differentiation upon exiting the niche. BTICs share some cell-autonomous regulatory pathways with neural stem cells but also independently create elements of the neural stem niche-for example, neovascularization. The neural stem cell niche is a structural construct but also is associated with regional variation in oxygen, pH and nutrient availability. Thus, it is almost certain that metabolic reprogramming that occurs in the context of oncogenesis represents an element of the BTIC niche that requires control of metabolic stress responses.
Neurons express the high-affinity glucose transporter, GLUT3, which allows these cells to outcompete their neighbors (for example, astrocytes that express predominantly GLUT1) for limited nutrition. We recently demonstrated that BTICs have co-opted GLUT3 expression to maintain themselves in the context of the limited nutrient conditions found in tumors 19 . With advances in gene expression analysis in cancer and transcriptional control of BTICs, comparative gene expression strategies have been widely used to discover new molecular targets in cancer studies. These observations extend to BTIC discovery approaches with many targets that show elevated expression in BTICs in comparison to non-BTIC tumor cells 44 . We now report that BTIC control can extend beyond the scope of differentially regulated genes at the transcriptional level, such as the gene encoding GLUT3 (SLC2A3), through a linkage to post-translational metabolic control. BTICs display preferentially fragmented mitochondrial morphology relative to non-BTIC tumor cells, and this is driven by augmented fission. The balance between mitochondrial fission and fusion is controlled by a small cohort of mediators (OPA1, MFN1 and MFN2 for fusion and DRP1 for fission) 22 . While the total protein levels of these mediators were not differentially regulated in the tumor hierarchy, DRP1 activation and localization was skewed toward the stem-like tumor cells. This functional difference was driven by an unbalanced ratio of the post-translational regulation of DRP1 phosphorylation toward activation and away from inhibition. Our data suggests that, beyond gene expression, protein modifications-including phosphorylation, acetylation, methylation, SUMOylation and ubiquitinationoffer worthwhile avenues for further exploration in BTIC research. (d-f) Analysis of REMBRANDT data indicates that higher CDK5 (P = 0.0046 by log-rank analysis) and lower CAMK2 mRNA expression (P = 0.047 and 0.0023 by log-rank analysis for CAMK2A and CAMK2G, respectively) correlate with poor glioma patient survival. npg a r t I C l e S Metabolism represents a domain for potential cancer therapeutic for BTICs. While IDH1 mutations promote chromatin alterations throughout a tumor to promote a loss of differentiation that can be targeted by small molecules, IDH1 mutations are infrequent in glioblastoma 14 . Postmitotic neurons express CDK5, which can serve to control metabolism even in non-cycling neurons. Limited previous reports have suggested that CDK5 is expressed by glioma cell lines and may contribute to cell invasion and survival after radiation, phenotypes found in BTICs [45] [46] [47] . Thus, it appears that BTICs have co-opted another neuronal metabolic control mechanism to augment cellular survival to promote tumor growth.
Aberrant metabolism is not solely a byproduct of mutations or altered transcriptional programs, but represents a driving force in the initial stages of tumorigenesis. Recently, studies of BTIC metabolism in glioblastoma and leukemia have yielded discordant responses in relative dependence on glycolysis versus oxidative phosphorylation and reactive oxygen species levels, but it is clear that the metabolic state of BTICs varies within the cellular hierarchy, as in the hierarchy of the normal hematopoietic system [17] [18] [19] 48 . As a highly specialized and dynamic organelle, the mitochondrion must be central to these distinctive features in energy metabolism. We found that inhibition of DRP1-mediated mitochondrial fission decreased cellular oxygen consumption rate and caused metabolic stress in BTICs. In addition, we detected AMPK activation in response to such energy homeostasis, supporting the idea that energy stress is present. The depletion of AMPK largely rescued the antiproliferative and proapoptotic effects of DRP1 targeting, which is consistent with AMPK function as a tumor suppressor in BTICs 41 . Future studies may show that combining DRP1 inhibition (for example, through Mdivi-1) and AMPK activation (for example, through 5-amino-1-β-d-ribofuranosyl-imidazole-4-carboxamide (AICAR)) may create additional synergy. As DRP1 expression and AMPK activity may be altered in response to cytotoxic ionizing radiation treatment, these therapeutic modalities may have even greater impact when used in combination. In sum, our results implicate a close interaction between DRP1 controlled mitochondrial fission and AMPK-mediated energy stress response that awaits further detailed study of the molecular mechanism of regulation of AMPK activity by DRP1 and mitochondrial dynamics.
Our discovery of a prosurvival function of DRP1 in BTICs is particularly exciting as targeting DRP1 may increase survival of normal brain cells and improve toxicity of chemotherapy. We found that targeting DRP1 by RNA interference or a pharmacologic inhibitor retarded cell growth and induced apoptosis in BTICs, with limited toxicity against normal human NPCs. In contrast with its role in BTICs, DRP1 inhibition is advancing as a target in treatment to alleviate neuronal death in Alzheimer's, Parkinson's and Huntington's diseases 22 . For example, a recent report showed that treatment of a genetically engineered mouse model of Huntington's disease with P110-TAT, another inhibitor of DRP1, strongly reduced neurological defects 49 . Thus, systemic inhibition of DRP1 may not only directly target BTIC self-renewal and growth but also function as a protector of normal neural cells. These efforts by the neuroscience community are driving not only the development of these agents but, with a focus on CNS delivery, permitting a potentially rapid translation into the treatment of glioblastoma and perhaps brain metastases. Our results do not rule out a loss of fusion in BTICs, but targeting fission holds several distinct advantages as a therapeutic target over fusion regulators. First, DRP1 has already been shown to be a critical mediator of fission, providing a single target rather than three targets with distinct expression and function. Second, DRP1 is an enzyme (GTPase) that can be inhibited with acceptable activity, especially in the brain. Finally, DRP1 inhibitors are already in early development on the basis of a benefit for neurodegenerative diseases, suggesting a potential neuroprotective effect. Although the role of mitochondrial fission in neurodegeneration and other systemic toxicity caused by radiation and chemotherapy treatments has not been well investigated, it is encouraging to think that these approaches may simultaneously treat the tumor and attenuate the negative effects of conventional therapy.
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